Federico Depuy, MD
Cardiovascular Disease · Baton Rouge, LANPI 1831535186
Payments from drug & device makers
Across 459 payments — averaging $148.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$24K
- Medtronic$17K
- Edwards Lifesciences$8K
- Penumbra, Inc.$5K
- Abiomed$3K
- Boston Scientific$3K
- plus $8K from 31 others
What the payments were for
- Consulting fees$1,5902%
- Speaking & faculty fees$18,70027%
- Grants$3951%
- Travel & lodging$25,14937%
- Food & beverage$22,21133%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 49 | $24,295 |
| Medtronic(2 entities) | 96 | $17,272 |
| Edwards Lifesciences | 61 | $7,762 |
| Penumbra, Inc. | 18 | $5,197 |
| Abiomed | 32 | $3,459 |
| Boston Scientific | 40 | $2,525 |
| Terumo Medical Corporation | 13 | $957 |
| Abbott | 14 | $937 |
| Ancora Heart, Inc. | 2 | $751 |
| Inari Medical, Inc. | 8 | $736 |
| Cook Incorporated | 4 | $731 |
| Asahi Intecc USA, Inc. | 9 | $575 |
| Johnson & Johnson | 18 | $487 |
| AstraZeneca | 22 | $351 |
| Cardiovascular Systems Inc. | 4 | $299 |
| Chiesi USA, Inc. | 7 | $186 |
| Angiodynamics, Inc. | 1 | $183 |
| Novartis | 12 | $174 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $162 |
| Esperion Therapeutics, Inc. | 2 | $125 |
| Philips North America LLC | 1 | $116 |
| Kestra Medical Technology Services, Inc. | 5 | $114 |
| E.r. Squibb & Sons, L.L.C. | 7 | $108 |
| Acist Medical Systems, Inc. | 1 | $80 |
| Amgen | 4 | $74 |
| Pfizer | 4 | $62 |
| Amarin Pharma, Inc. | 3 | $57 |
| Cardiva Medical, Inc. | 2 | $57 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $38 |
| Aroa Biosurgery Incorporated | 1 | $34 |
| Alnylam Pharmaceuticals Inc. | 1 | $33 |
| Solventum Corporation | 1 | $26 |
| Livanova USA, Inc. | 1 | $24 |
| Heartflow, Inc. | 1 | $21 |
| Novo Nordisk | 1 | $21 |
| Bayer | 1 | $17 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$23,042
- Indigo System$3,768
- Impella$2,656
- Edwards SAPIEN 3 Transcatheter Heart Valve$2,365
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$2,161
- RESOLUTE ONYX$1,251
- SAPIEN 3 Ultra RESILIA$1,126
- Penumbra Coil 400$1,110
- CoreValve Evolut$1,066
- ONYX FRONTIER$852
- COREVALVE EVOLUT R$812
- GlideWire$682
- AccuCinch$652
- Cook Celect$619
- FLOWTRIEVER CATHETER, S$557
- CT THROMBECTOMY SYSTEM KIT$557
- Micra$502
- ASAHI PTCA Guide Wire$257
- Vascular Lithotripsy$219
- Auryon Laser System 100-120 Vac$183
How this compares
$68,059 in reported general payments places this provider in the 90th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 78 | $52,964 |
| FarxigaDapagliflozin Propanediol | 63 | $49,335 |
| EliquisApixaban | 53 | $44,579 |
| JardianceEmpagliflozin | 29 | $26,389 |
| EntrestoSacubitril/Valsartan | 24 | $24,550 |
| BrilintaTicagrelor | 47 | $21,169 |
| Rosuvastatin Calcium | 238 | $3,295 |
| Ezetimibe | 106 | $2,393 |
| Metoprolol Succinate | 174 | $2,150 |
| Amiodarone Hcl | 25 | $2,113 |
| Valsartan | 40 | $1,051 |
| ClopidogrelClopidogrel Bisulfate | 75 | $771 |
| Chlorthalidone | 37 | $665 |
| Atorvastatin Calcium | 65 | $615 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 59 | $584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $351 | $70,504110 claims |
| PfizerEliquis | $62 | $44,57953 claims |
| NovartisEntresto | $174 | $24,55024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Baton Rouge
- George KaramBaton Rouge$110K
- Tara JarreauBaton Rouge$64K
- James BarriosBaton Rouge$43K
- Paul GarrettBaton Rouge$24K
- Cordel ParrisBaton Rouge$24K
- Ghiath MikdadiHammond$5.7M
- Marc BernsteinSlidell$2.1M
- Anil ChhabraShreveport$1.9M
- Dale PresserCovington$1.7M
- William EavesShreveport$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.